Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab combined with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.
Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab (Monjuvi) combined with lenalidomide (Revlimid) for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.
According to Salles, 50% of patients experienced a drop in white blood cell count and 1/3 of patients required an injection to boost count. Additionally, 1 in 6 patients experienced infection that may led to hospitalization. Most of these infections were common, however some lead to hospitalization. No instances of septic shock were reported.
Anemia occurred in 1/3 of patients. Patients also experienced platelet cell diminishment. One in 6 patients required treatment for these adverse events.
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More
Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL
April 1st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.
Read More
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
March 21st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.
Read More